GEN Exclusives

More »

GEN News Highlights

Back to Item »

BARDA Rejects Maxygen’s Proposal to Develop MAXY-G34 for Acute Radiation Syndrome

BARDA cited issues like reliance on overseas manufacturing, dependence on subcontractors, and IP uncertainty.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »